dorma+kaba Holding AG reported record adjusted EBITDA margin of 16.1% for fiscal 2026, with organic sales growth of 3% and a strong second-half acceleration to 4%. Net sales reached CHF2,792.4 million, though currency translation reduced reported sales by 4.9%. The company proposed a simplified ownership structure that would create CHF2.1 billion in capital reserves, enabling tax-free dividends for Swiss shareholders, and received an investment-grade BBB rating from Standard & Poor's. Management guided to organic growth above 3% for fiscal 2026/27, citing a volatile environment, and announced a transition to IFRS reporting with a new operating profit margin guidance of at least 100 basis points improvement.
Dorma Kaba Holding AGReported record adjusted EBITDA margin of 16.1%, 3% organic growth, and an investment-grade BBB rating, plus a proposed ownership simplification creating CHF2.1bn in capital reserves.
Novartis AG